# The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors

> **NCT02050243** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Central Nervous System Tumor, Pediatric

## Interventions

- **DRUG:** 5ALA

## Key facts

- **NCT ID:** NCT02050243
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-02
- **Primary completion:** 2016-02
- **Final completion:** 2017-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2014-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02050243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02050243, "The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02050243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*